Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

122
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
122
Dementia01:30

Dementia

113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
113
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Drug Therapy01:28

Drug Therapy

43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
43
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postmortem brain MRI reveals differential associations of subcortical and limbic volumes with cortical thinning and neurodegenerative pathologies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Characteristics and clinical correlates of objective medication adherence in older adults with cognitive impairment.

The Clinical neuropsychologist·2026
Same author

When stigma hits home: A mixed methods study of affiliate stigma among epilepsy care partners.

Epilepsy & behavior : E&B·2026
Same author

Clinicoanatomic localization of iron-rich gliosis in aphasic presentations of globular glial tauopathy.

Brain communications·2026
Same author

The physiological effects of APOE genotype in healthy young/middle-aged individuals.

Biological reviews of the Cambridge Philosophical Society·2026
Same author

Subjective and objective cognition in early-stage, treatment-naïve Parkinson's disease: Relationships with mood.

Neuropsychology·2026

Related Experiment Video

Updated: Jun 29, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K

Medication management error types: Associations with mild cognitive impairment subtype.

Alyssa N De Vito1,2, Sheina Emrani3, Emily Hallowell1,4

  • 1Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA.

The Clinical Neuropsychologist
|April 8, 2024
PubMed
Summary

Older adults with multi-domain mild cognitive impairment (MCI) made more medication errors. Single-domain MCI patients showed more perseverative errors, potentially overcompensating for memory loss.

Keywords:
Mild cognitive impairmentecological validityeveryday functioningmedication managementmedication management ability assessment

More Related Videos

The Double-H Maze: A Robust Behavioral Test for Learning and Memory in Rodents
09:01

The Double-H Maze: A Robust Behavioral Test for Learning and Memory in Rodents

Published on: July 8, 2015

12.6K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

32.3K

Related Experiment Videos

Last Updated: Jun 29, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K
The Double-H Maze: A Robust Behavioral Test for Learning and Memory in Rodents
09:01

The Double-H Maze: A Robust Behavioral Test for Learning and Memory in Rodents

Published on: July 8, 2015

12.6K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

32.3K

Area of Science:

  • Gerontology
  • Neuropsychology
  • Pharmacology

Background:

  • Medication management errors are a significant concern for older adults, particularly those with cognitive impairments.
  • Mild cognitive impairment (MCI) presents a spectrum, with varying impacts on daily functioning.

Purpose of the Study:

  • To investigate and compare simulated medication-taking errors across cognitively normal (CN) older adults and those with single-domain amnestic MCI (sdMCI) and multi-domain MCI (mdMCI).
  • To identify specific types of errors, including omission, commission, and perseveration, associated with different MCI subtypes.

Main Methods:

  • Utilized the Medication Management Ability Assessment (MMAA) version 4.1, a performance-based task, with 266 participants (CN, sdMCI, mdMCI).
  • Employed Kruskal-Wallis H tests to analyze group differences in total scores, accuracy, and error types.
  • Introduced and operationalized 'perseverative errors' as taking a dose multiple times.

Main Results:

  • Individuals with mdMCI demonstrated significantly lower overall performance (MMAA scores) compared to CN and sdMCI groups.
  • The mdMCI group exhibited a higher frequency of omission errors (missed doses).
  • The sdMCI group made more perseverative errors than the CN group, while no significant differences in commission errors were observed between groups.

Conclusions:

  • Multi-domain MCI is associated with a higher vulnerability to medication management difficulties.
  • Perseverative errors in sdMCI may indicate compensatory strategies for memory deficits.
  • Further research is needed to correlate MMAA performance with real-world medication adherence in diverse populations.